| Name | Title | Contact Details |
|---|
Discovering new medicines by combining ultra throughput biochemistry and machine learning.
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasΦ, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.
Cellnetix is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Spinemark is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Genemed Synthesis, Inc. is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.